2016 American Society of Hematology Annual Meeting*

Download All
December 3-6, 2016; San Diego, California
Rami S. Komrokji, MD, and Jamile Shammo, MD, FASCP, FACP, review data from key MDS and MPN presentations at the 2016 American Society of Hematology Annual Meeting.
Rami S. Komrokji, MD
Jamile Shammo, MD, FASCP, FACP

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Overall reduction of splenomegaly by > 50% occurred in 79% of MF patients on combination ruxolitinib plus azacitidine.

Released: December 7, 2016

Lenalidomide can restore epoetin alfa sensitivity in lower-risk MDS patients refractory or unresponsive to erythropoiesis stimulating agents.

Released: December 6, 2016

ORR 60% among patients with lower-risk MDS treated with low-dose azacitidine or decitabine.

Released: December 6, 2016

Daily oral enasidenib monotherapy shows activity in a small cohort of patients with predominately high-risk mIDH2 MDS, including some who failed prior HMA treatment.

Released: December 6, 2016

Preliminary phase II data suggest promising activity of single-agent ipilimumab and nivolumab plus azacitidine in a molecularly high-risk population of MDS patients.

Released: December 9, 2016

Results from the phase III trial showed fewer treatment-related AEs, dose reductions, and secondary malignancies in patients receiving ropeginterferon α-2b compared with those receiving hydroxyurea.

Released: December 7, 2016

Sotatercept well tolerated with response observed in 36% of evaluable patients.

Released: December 8, 2016

Results from interim analysis of phase III trial found no difference in CR at 12 months between therapies, and grade ≥ 3 AEs occurred more frequently in patients receiving pegIFN α-2a.

Released: December 8, 2016

In this Expert Analysis, Jamile Shammo, MD, FASCP, FACP, and Rami S. Komrokji, MD, discuss the clinical applicability of new, key findings in myelodysplastic syndromes and myeloproliferative neoplasms presented at Hematology 2016.

Rami S. Komrokji, MD Jamile Shammo, MD, FASCP, FACP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: January 24, 2017 Expired: No longer available for credit

In this downloadable slideset, Rami S. Komrokji, MD, and Jamile Shammo, MD, FASCP, FACP, highlight the key data presented at the 2016 Hematology annual meeting.

Released: December 19, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation
Merck & Co., Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings